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Therapeutic drug monitoringMammalian target of rapamycin (mTOR)-inhibitor-containing immunosuppressive regimens have been devel-
oped as part of calcineurin inhibitor (CNI) minimization/withdrawal strategies for renal transplant recipients,
with the goal of avoiding CNI-associated nephrotoxicity. This review focuses on the pharmacokinetic interactions
and exposure–response relationships of mTOR inhibitors and tacrolimus (TAC), the most widely used CNI. We
also discuss key randomized clinical studies that have evaluated use of this combination in renal transplantation.
Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large
intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0]
3–8 ng/mL and 5–15 ng/mL, respectively). Consequently, routine therapeutic drug monitoring of EVR and SRL
is recommended to optimize efﬁcacy and minimize toxicity in individual patients. As there is a good correlation
between C0 and area under the curve (AUC), C0 can be used as a convenient and reliable measure of mTOR drug
exposure. Clinical data on the use of EVR or SRL in TAC minimization strategies in renal transplantation are lim-
ited. Available evidence suggests that treatment with EVR allows early and substantial TAC minimization when
used with basiliximab induction and corticosteroids, to achieve good renal function without compromising
efﬁcacy or safety. However, data comparing this combination with other regimens are lacking. Results with
SRL are more mixed. SRL in combination with reduced TAC has been shown to provide less nephrotoxicity
than the SRL/standard TAC combination, with comparable efﬁcacy and safety. However, this approach has
been shown to be inferior to other regimens in terms of patient/graft survival and biopsy-proven acute rejection
(vs MMF/TAC) as well as renal function (vs MMF/TAC and SRL/MMF). Further studies are needed to deﬁne the
therapeutic window for TACwhen used in combination withmTOR inhibitors, evaluate EVR/reduced TAC versus
other regimens, assess long-term outcomes, and determine efﬁcacy and safety in high-risk patients.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Since becoming available over 3 decades ago, the calcineurin inhibi-
tors (CNI), cyclosporine A (CsA) and tacrolimus (TAC), have become,
and remain, the cornerstoneofmaintenance immunosuppressive therapy
in renal transplantation [1,2]. The introduction of CNIs in the 1980s result-
ed in lower rejection rates and improved short-term patient and allograft
survival rates, with 1-year graft survival rates of around 90% and acute re-
jection rates below 20% being achieved. Despite these impressive 1-year
rates, long-term improvements in graft survival have been more difﬁcult
to achieve with CNIs. Indeed, the reduction in acute rejection with these
drugs has not directly translated to improvements in allograft survival,
and suggests that CNI-based immunosuppression may not improve
long-term graft survival [1].
The main reason for this observation is that long-term CNI use
gives rise to nephrotoxicity, which is an important cause of long-
term graft failure [3]. Indeed, nephrotoxicity is present in 96.8% of
kidney allograft biopsies by 10 years [4]. CNIs initially protect the
renal transplant against immunologic injury but may subsequently
cause damage as a result of long-term nephrotoxicity. This helps, at
least partly, to explain why the low early acute rejection rates
achieved using CNIs are not accompanied by improvements in
long-term outcomes [4].
As a consequence, CNI-sparing/withdrawal strategies are employed
to minimize CNI nephrotoxicity under the protection of additional im-
munosuppressant drugs [1,4]. One approach is to use 2-stage immuno-
suppression, with stage 1 using CNIs to minimize immunogenic injury
and stage 2 using long-term “nonnephrotoxic” immunosuppression
[4]. The emergence of powerful nonnephrotoxic agents such as the
mammalian target of rapamycin (mTOR) inhibitors has facilitated CNI
reduction/withdrawal early posttransplantation [1]. The need to reduce
nephrotoxicity, however, must be weighed against the increased risk of
acute rejection or chronic antibody-mediated rejection [5] that presents
with suboptimal CNI exposure [6]. ThemTOR inhibitors, sirolimus (SRL)
and everolimus (EVR), have an immunosuppressive mode of action
complementary to that of CNIs, which provides the rationale for their
combined clinical use [7–9]. CNIs act early after T-cell activation,
preventing transcriptional activation of early T-cell-speciﬁc genes. By
blocking calcineurin, the production of proinﬂammatory cytokines
(e.g. interleukin-2 [IL-2]) and, subsequently, T-cell activation are
inhibited. By contrast, mTOR inhibitors reduce T-cell activation later in
the cell cycle by blocking growth-factor-mediated cell proliferation in
the cellular response to alloantigen [3,8,10].
The distinct mechanism of action and favorable nephrotoxicity
proﬁle has led to mTOR-inhibitor-containing regimens being devel-
oped with the aim of minimizing, eliminating, or avoiding exposure
to CNIs. A number of studies have shown that the combination of
an mTOR inhibitor and CsA is safe and effective, and allows CsA min-
imization and elimination [3,10–12]. Withdrawal of CsA from SRL
maintenance therapy has also been shown to be a safe and effective
alternative to continuous therapy with CsA and SRL [3,11]. EVR com-
bined with reduced-dose CsA has been shown to be well tolerated,
with low efﬁcacy failure and better renal function, compared with
EVR combined with full-dose CsA [10]. Further, EVR with progressive
reduction in CsA dose of up to 60% at 1 year resulted in similar efﬁcacy
and a trend towards improved renal function, comparedwith standard-
exposure CsA in combination with mycophenolic acid (MPA) [12].TAC-based regimens, however, are the most frequently used regi-
mens in clinical practice for both initial and maintenance immunosup-
pression (N80% and N70%, respectively, of renal transplant recipients).
Between 1998 and 2009, the use of TAC increased from around 26% to
88% [13]. As a result, TAC has largely supplanted CsA over the past
10 years. Indeed, the Kidney Disease Improving Global Outcomes
(KDIGO) clinical practice guidelines for the care of kidney transplant
recipients recommend the use of TAC as the ﬁrst-line CNI for initial
maintenance therapy in combination with an antiproliferative
agent, with or without corticosteroids [14]. The need to develop reg-
imens that allow TAC minimization is, therefore, an area of clinical
importance.
Another important consideration is that CNIs have a narrow thera-
peutic window (exposure for efﬁcacy is close to that causing toxicity),
with drug over- and under-exposure leading to potentially serious con-
sequences. Achieving the optimal dose in clinical practice is often chal-
lenging because of inter- and intra-individual CNI pharmacokinetic
variations [2]. In particular, after a CNI dose there is considerable
variability in blood–drug concentrations between individuals [15].
Therefore, to optimize treatment outcomes careful therapeutic drug
monitoring (TDM) is required [2]. Most clinicians prescribing CNIs use
blood concentration measurements to guide dosing. When administer-
ing TAC, trough concentration (C0) monitoring is commonly used as a
basis for individualizing treatment [15,16] because, unlike CsA, there
is a relatively good correlation between TAC exposure and C0.
TDM has been recommended for many other immunosuppressive
drugs. A consensus group concluded that although routine TDM of
MPA is not recommended, speciﬁc patient groups such as those at
heightened immunologic risk, undergoing minimization or withdrawal
of immunosuppressive therapy, or experiencing altered hepatic, renal,
or bowel function could beneﬁt from TDM [17]. There is, however, cur-
rently no evidence that MPA TDM has an impact on graft outcomes or
patient survival. AsmTOR inhibitors have a narrow therapeutic window
and variable oral bioavailability, TDM is also advocated for these drugs
[18]. Much of the information on mTOR inhibitor TDM is derived from
the use with CsA-based regimens, but data on use with TAC are gradu-
ally accumulating.
This review examines recent data on the combined use of mTOR in-
hibitors and CNIs, with a particular focus on TAC, the most widely used
CNI. Pharmacokinetic interactions, exposure–response relationships,
and key randomized clinical studies using concentration-controlled
dosing of these agents are reviewed.
2. Pharmacokinetic characteristics of mTOR inhibitors
The oral bioavailability of mTOR inhibitors is low (14% for SRL and
20% for EVR) [19]. SRL and EVR are both metabolized extensively by
cytochrome P (CYP)-450 3A in the liver and intestines, and affected
by the different activities of the drug efﬂux pump P-glycoprotein,
which leads to the low bioavailability observed with these drugs
[18,20].
In renal transplant patients receiving escalating single oral doses of
SRL (3–21 mg/m2) in combination with CsA and corticosteroids, the
maximum concentration (Cmax) ranged between 14 and 344 μg/L, and
was reached (tmax) in 0.5 to 3 h [21]. In renal transplant patients receiv-
ing single oral doses of EVR (0.25 to 25 mg) in combination with CsA
and corticosteroids, Cmax was found to be between 2.3 and 179 μg/L
24 F. Shihab et al. / Transplant Immunology 31 (2014) 22–32and reached in 1 to 2.2 h [18]. Unlike dosing with SRL, however, where
the dose correlates only modestly with either Cmax or with area under
the curve (AUC) [21,22], EVR displays dose-proportional pharmacoki-
netics with rapid absorption leading to attainment of peak blood con-
centrations within 1–2 h after oral dosing [18]. Demographic factors,
such as sex, age, or body weight do not affect the pharmacokinetics of
EVR or SRL in adults [23,24].
With EVR, steady state is reached within 4 days with an accumula-
tion in blood levels of 2- to 3-fold compared with the exposure after
the ﬁrst dose [19,25]. In de novo renal transplant recipients receiving
EVR, CsA, and corticosteroids, steady-state Cmax, C0, and AUC showed
a dose-proportional increase. This steady-state, dose-proportional effect
was maintained over 1 year [23]. Importantly, the predose C0 of EVR
correlated well with AUC over the year-long study. This demonstrates
that C0 provides a simple, reliable index for the TDM of EVR [23,26]; a
similar relationship has been observed for SRL [20–22]. As over 75%
of EVR and 94% of SRL in blood is sequestered into erythrocytes,
whole-blood samples are appropriate for measuring systemic levels
and for TDM [18,21].
Around 98% of EVR is excreted as metabolites in the bile and the
remainder in the urine. EVR has an elimination half-life of approxi-
mately 30 h [19]. Prescribing information recommends EVR be ad-
ministered twice daily (bid) in transplant recipients, mainly
because of the CsA/EVR interaction described in the following sec-
tion; however, preliminary evidence in renal transplant recipients
suggests similar efﬁcacy (e.g. patient survival and graft survival,
acute rejection episodes) and renal function with once-daily versus
twice-daily EVR dosing when given with CNIs [27–29]. The main
route of clearance for SRL is also biliary; with 91% of SRL metabolites
found in feces and 2.2% in urine [21]. SRL has a longer elimination
half-life of 62 h. The long half-life requires a loading dose if steady-
state concentrations are to be reached quickly, but it also enables
once-daily SRL dosing [21]. A number of metabolites have been identi-
ﬁed for both SRL and EVR, but these display minimal activity [20,30].
EVR has 4 main metabolites: hydroxy-EVR, dihydroxy-EVR, demethyl-
EVR, and the ring-opened form of EVR [18]. SRL forms demethylated,
monohydroxylated, dihydroxylated, and didemethylated metabolites
[20].
Intra- and inter-patient variability in both EVR and SRL exposure has
been found to bemoderate to high. Themean values of intra- and inter-
patient variability in AUC has been determined for both EVR (27% and
31%, respectively) [26] and SRL (64% and 60%, respectively) [22] when
administeredwith CsA and corticosteroids in de novo kidney transplant
patients. Demographic factors including sex, age, or weight did not con-
tribute to the inter-patient variability of EVR. Black patients, however,
had a 20% lower exposure to EVR compared to white patients although
it is unclear what role reduced bioavailability and/or increased clear-
ance has to play in this observation. This lower exposure requires a
higher dose of EVR to achieve the therapeutic range andmay help to ex-
plain the reduced efﬁcacy that has been demonstrated in black patients
in some but not all analyses [26,31]. The intra- and inter-patient vari-
ability in drug exposure emphasizes the need for TDM with EVR and
SRL [22].
It can be seen that SRL and EVR share several pharmacokinetic
characteristics, including high intra- and inter-patient variability
and correlation of C0 with exposure. The main difference is the longer
half-life of SRL; this allows for once-daily administration but may
make it more difﬁcult to manage in the event that interruption of
therapy is necessary.
3. Drug interactions between mTOR inhibitors and Tac
The mTOR inhibitors and CNIs are all substrates of hepatic and
intestinal CYP3A4 enzymes and P-glycoprotein. Competition for
these shared biotransformation or transport pathways may interfere
with the absorption or elimination of the drugs, potentially leadingto clinically signiﬁcant alterations in exposure when these agents
are coadministered [18,21].
The current recommended standard oral dosage of TAC when ad-
ministered with mycophenolate mofetil (MMF) and an induction
agent is 0.1 mg/kg daily (administered as 2 divided doses 12 h apart).
When administered over months 1 to 12, this dosage has resulted in a
C0 of 4–11 ng/mL [32].
3.1. Interactions between EVR and TAC
Few studies have characterized the pharmacokinetics of EVR and
TAC when used in a combined immunosuppressive regimen. An open-
label, exploratory study evaluated the pharmacokinetics of EVR and
TAC in 8maintenance renal transplant patientswith CNI intolerance ini-
tially receiving MMF and TAC [33]. At the start of the study, MMF was
stopped and replaced with EVR (1.5 mg bid) during days 1 and 10
(period 1). Between day 11 and month 3 (period 2), the TAC dose was
reduced by 50%. EVR 1.5 mg bid did not inﬂuence the pharmacokinetics
of standard-dose or reduced-dose TAC. The addition of EVR did not alter
TAC C0, compared to baseline (7.9± 3.9 ng/mL; p= 0.57). In addition,
there were no differences in Cmax (p = 0.38) or AUC (p = 0.64) when
EVR was added. During period 2, when the TAC dose was reduced by
half, C0, Cmax, and AUC decreased by 46%, 41%, and 45%, respectively.
TAC had minimal inﬂuence on EVR levels. The C0 of EVR remained sta-
ble over the course of the study, regardless of administration with full-
dose TAC or reduced-dose TAC (p= 0.55); AUC of EVR was reduced by
13% (p = 0.052) and Cmax by 14% (p = 0.37) when administered with
reduced-dose TAC.
These results with TAC can be compared with pharmacokinetic
data from a trial of 47 renal transplant patients in which a similar
dose of EVR was used in combination with CsA. This cross-study
comparison suggested that at steady state (month 6), C0 (8.2 ±
4.3 ng/mL), Cmax (21 ± 8.2 ng/mL), and AUC (138 ± 52 ng·h/mL)
of EVR were 2.5-fold higher after coadministration with CsA than with
TAC [33]. A similar effect has been observedwhen patients are switched
between CNIs. In a small study in cardiac transplant recipients treated
with TAC and EVR, the EVR exposure was lower when patients were
converted from CsA to TAC [34]. When patients were converted from
CsA to TAC under continuous EVR therapy, a signiﬁcant decrease in
EVR C0 (from 4.2 to 2.3 μg/L), Cmax (from 9.1 to 5.9 μg/L), and AUC
(from 64.2 to 33.7 μg·h/L) was found, indicating a lower EVR exposure
(p b 0.05). This demonstrates the importance of higher EVR start doses
with TAC than recommended for CsA in order to avoid increased risk of
rejection.
Another, more recent, study has also shown an absence of any
signiﬁcant pharmacologic interaction between EVR and TAC [35].
In the 6-month multicenter US09 study, 92 de novo renal transplant
recipients were randomized to receive EVR (initiated at 1.5-mg bid
and adjusted to maintain C0 ≥ 3 ng/mL) plus reduced-dose TAC
(4–7 ng/mL months 0–3; 3–6 ng/mL months 4–6) or standard-dose
TAC (8–11 ng/mL months 0–3; 7–10 ng/mL months 4–6). Both groups
received basiliximab and corticosteroids. Exposure to EVRwas unaffect-
ed by concomitant dosing with TAC and no apparent pharmacokinetic
interactions existed. Both TAC and EVR AUCs were stable over time.
However, because of numerically higher dose-normalized AUC values
for TAC in the lower dose TAC group (Fig. 1), a possible effect of EVR
on TAC exposure could not be ruled out and requires further investiga-
tion in a larger trial. Patients received varying doses to achieve target
drug levels; thus, AUC values were dose-normalized, i.e., the observed
AUC value was divided by the dose recorded at the time closest to the
AUC measurement.
In contrast to theﬁndings of the 2 previous studies that suggestmin-
imal pharmacokinetic interaction between EVR and TAC, another recent
study evaluating the impact of ﬁxed low or high EVR doses on systemic
exposure to TAC following combined administration, showeddecreased
TAC exposure following concomitant administration with EVR [36]. In
Fig. 1.Mean tacrolimus exposure atmonths 1, 3, and 6 [35]. NB. All between-group differ-
ences were nonsigniﬁcant at each time point. AUC, area under the curve.
Figure taken from Chan et al. 2010. Reprinted with permission from Chan L,
Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is as-
sociated with risk reduction for acute rejection in de novo renal transplant recipients.
Transplantation 2010;90:31–7.
25F. Shihab et al. / Transplant Immunology 31 (2014) 22–32the EVEROTAC 6-month prospective, open-label pharmacokinetic
study, 35 renal transplant patients were randomized to receive EVR
0.75-mg bid or 1.5-mg bid in combination with standard-dose TAC
(0.075-mg/kg bid adjusted to achieve target C0 of 10–15 ng/mL from
days 1–14 posttransplant, and then 5–10 ng/mL thereafter to month
6). EVR C0 levels were maintained between 3 and 8 ng/mL from day
42. From day 4 onward, exposure to TAC was similar with both doses
of EVR (AUC: 162 ± 61 vs 171 ± 75 ng·h/mL). Signiﬁcant differences
in AUC were not seen, despite the EVR dose, because TAC dosing was
adjusted to achieve target levels. Although the pharmacokinetic data
suggest that neither EVR dose resulted in statistically signiﬁcant differ-
ences in TAC exposure, the doses of TAC required to maintain target
concentrations were higher when administered with EVR 1.5 mg bid
than with EVR 0.75-mg bid (12.5 mg vs 9.5 mg at day 14, and 9 mg vs
6 mg at day 42; p b 0.05 for both comparisons). Further, EVR appeared
to decrease TAC exposure in a concentration-dependent manner. The
data suggest that concomitant treatment with EVR 1.5-mg bid was
effective in minimizing exposure to TAC. However, further minimiza-
tion of TAC exposure would likely require doses of EVR greater than
3 mg/day because this dose was not enough to achieve EVR levels
N3 ng/mL during the ﬁrst 2 weeks.
From the limited data discussed above, the ﬁndings suggest that co-
administration with TAC does not inﬂuence exposure to EVR. The re-
ported effects of EVR on TAC exposure, however, are, inconsistent.Fig. 2. Mean dose-normalized (A) TAC exposure and (B) SRL exposure [37]. AUC, area
under the curve; SRL, sirolimus; TAC, tacrolimus.
Figures taken from Park et al. 2009. Reprinted with permission from Park et al. 2009. [37].3.2. Interactions between SRL and TAC
There are only limited published data evaluating the interaction
between SRL and TAC. In a recent pharmacokinetic study, both
time- and concentration-dependent increases in TAC and SRL were
reported. The study assessed drug exposure in 25 de novo kidney
transplant patients, who, within 24 h of the transplant surgery
were randomized to receive either SRL (15-mg loading dose, 5 mg
for 7 days, and 2 mg thereafter) or MMF (2 g/day) for 6 months
[37]. Both groups received TAC (0.10–0.15 mg/kg/dose) and cortico-
steroids. TAC doses were adjusted to keep blood concentration be-
tween 10 and 20 ng/mL for the ﬁrst 30 days, 8–15 ng/mL during
months 2 and 3, and 5–10 ng/mL thereafter. From day 7 to month 6,dose-normalized AUC0–12 for TAC increased by 59% in patients receiving
SRL and 65% in patients receivingMMF. Over the same period, the dose-
normalized AUC0–24 for SRL increased by 65%. Direct concentration-
dependent correlations occurred between TAC and SRL blood levels. In-
creasing TAC or SRL doses were associated with parallel increases in ex-
posure of SRL (p = 0.016) and TAC (p = 0.012), respectively (Fig. 2A
and B). These interactions suggest that intense TDM of SRL is required
to avoid under- or over-immunosuppression.
Another small randomized study (N = 16) showed that TAC expo-
sure was reduced after addition of SRL to TAC-based immunosuppres-
sion [38]. The study analyzed the pharmacokinetic interaction of 2
low-dose SRL regimens (0.5 mg/day or 2 mg/day) with full-dose TAC
(target C0 8–16 ng/mL for the ﬁrst 14 days and 5–15 ng/mL thereafter).
After 6 months, SRL was withdrawn and the daily TAC dose remained
the same in stable adult renal transplant recipients. Pharmacokinetic
parameters were measured on the day before SRL withdrawal and
then 15 days afterwards. Despite the use of low doses of SRL, dose-
dependent decreases in TAC AUC, Cmax, and C0 were observed.
Discontinuing SRL led to an increase in mean TAC levels in both groups.
After discontinuation, statistically signiﬁcant dose-dependent increases
in TAC AUC, Cmax and C0 (between 15% and 20% and 27% and 32% for the
SRL 0.5-mg and 2.0-mg doses, respectively) were seen. This suggests
that TAC levels require careful monitoring.
Fig. 3. Kaplan–Meier curve for time to BPAR by everolimus C0 [35]. BPAR, biopsy-proven
acute rejection.
Figure taken from Chan et al. 2010. Reprinted with permission from Chan L, Hartmann E,
Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with
risk reduction for acute rejection in de novo renal transplant recipients. Transplantation
2010;90:31–7.
26 F. Shihab et al. / Transplant Immunology 31 (2014) 22–32A study has also evaluated the long-term pharmacokinetic inter-
actions between SRL and TAC [39]. Nine de novo renal transplant
patients received standard-dose TAC (target C0 10–15 ng/mL during
the ﬁrst month and 8–12 ng/mL thereafter) combinedwith reduced-
dose SRL (target C0 5–10 ng/mL), or to reduced-dose TAC (target C0
3–7 ng/mL) combinedwith standard-dose SRL (target C0 10–12 ng/mL
in month 1, 10–15 ng/mL until month 3, then 8–15 ng/mL thereafter).
Twelve months of treatment with a combination of standard-dose
TAC and reduced-dose SRL was associated with increasing SRL dose
requirements to maintain constant exposure to SRL. This ﬁnding sug-
gested a possible effect of standard-dose TAC on long-term SRL
exposure.
Like EVR, SRL exposure is higher with CsA than TAC. In an open-label
parallel-group study of 22 de novo renal transplant patients random-
ized to receive either CsA (3 mg/kg; target C0 100–200 ng/mL) or TAC
(0.05 mg/kg, target C0 4–8 ng/mL) in combination with ﬁxed doses of
SRL (6-mg loading dose, then 2 mg/day), both Cmax and C0 were 42%
higher in the CsA group than the TAC group (p = 0.018 and 0.016, re-
spectively) [40]. Therefore, higher SRL start doses are needed with
TAC than with CsA.
It can be seen from the available data that the pharmacokinetic in-
teractions between TAC and SRL are inconsistent.
4. Exposure–response relationships and targetmTOR inhibitor levels
The therapeutic index of mTOR inhibitors (SRL and EVR) is nar-
row [18], and this drug class is associated with a high degree of
intra- and inter-individual variability in exposure [22,26]. Also
there is a clear relationship between C0 and acute rejection rates
and adverse events (AEs). Because of this, rather than ﬁxed dosing,
TDM is likely to provide optimal dosing and therefore, efﬁcacy and
safety [41].
Exposure–response evaluations have been used to establish a thera-
peutic concentration range for the safe and effective use of mTOR inhib-
itors for immunosuppression in renal transplantation. Such studies have
revealed that both immunosuppression and some AEs are dose- and
concentration-dependent [42].
4.1. Everolimus
Several studies have evaluated the exposure–response relationships
for EVR in renal transplant recipients receiving standard-dose or
reduced-dose CsA. They demonstrated that an EVR C0 of ≥3 ng/mL
leads to fewer episodes of acute rejection and graft loss than when the
C0 is b3 ng/mL. An EVR C0 range of 3–8 ng/mL provided the best bal-
ance between reduced risk of acute rejection and acceptable tolerability
[41–43]. An upper limit has yet to be deﬁned; indeed EVR C0 levels of
12 ng/mL have been shown to be well tolerated. Based on this, TDM is
recommended to maintain EVR C0 between 3 and 8 ng/mL [35].
Data on concentration–response relationships for EVR when used
with TAC in de novo renal transplant patients are limited. A post hoc
analysis of the US09 study has been carried out to determine whether
biopsy-proven acute rejection (BPAR) rates and AEs were dependent
of EVR C0 when used in a TAC-based immunosuppression regimen.
In the study, when patients (N = 92) received concentration-
controlled EVR (target trough levels ≥3 ng/mL) with reduced
(4–7 ng/mL months 0–3 and 3–6 ng/mL months 3–6) or standard
TAC exposure (8–11 ng/mL months 0–3 and 7–10 ng/mL months
3–6), EVR trough levels ≥3 ng/mL were associated with a signiﬁ-
cantly lower rate of BPAR compared with levels b3 ng/mL, regardless
of TAC target ranges (p = 0.03; Fig. 3) [35]. These results were con-
sistent with studies of EVR plus CsA that showed lack of rejection
with an EVR level ≥3 ng/mL [41–43].
Further, renal function and safety did not seem to differ by
trough EVR or TAC levels, with similar glomerular ﬁltration rates
(GFR) (EVR b3 ng/mL: low TAC 74.2 mL/min vs standard TAC68.8 mL/min; EVR 3–8 ng/mL: low TAC 75.5 mL/min vs standard
TAC 74.5 mL/min; EVR N8 ng/mL: low TAC 77.4 mL/min vs stan-
dard TAC 72.4 mL/min) and AE incidence in the groups with EVR
levels b3 ng/mL or 3–8 ng/mL, and low-dose or standard-dose
TAC [35]. The ﬁndings from this study, and the CsA studies, demon-
strate that EVR C0 should be maintained ≥3 ng/mL for optimal ef-
ﬁcacy with TAC, and that EVR C0 is useful for monitoring therapy.4.2. Sirolimus
A relationship between the SRL blood concentration and pharma-
cologic response has been shown when SRL is used as part of a CsA-
based regimen. In a cohort of 150 de novo renal transplant patients
treated with SRL, CsA, and corticosteroids, whole-blood SRL concen-
trations N5 ng/mL were associated with protection from acute
rejection episodes, whereas AEs were correlated with SRL trough con-
centrations N15 ng/mL [22]. This identiﬁes a SRL therapeutic window
of 5–15 ng/mLwhen SRL is usedwith CsA and steroids [22,24]. A similar
exposure–response assessment for SRL has not been performed in pa-
tients receiving TAC.
Data from pharmacokinetic studies have shown that SRL exposure is
lower when combined with TAC than CsA. In a randomized, long-term
study, 150 de novo renal transplant patients were randomized to re-
ceive TAC (target C0 10, 8, and 6 ng/mL at 1 month, 6 months, and
1 year, respectively) plus SRL (target C0 8 ng/mL); TAC (target C0 10
and 8 ng/mL at month 1 and 1 year, respectively) plus MMF (2 g); or
CsA (target C0 225 and 175 ng/mL at month 1 and 1 year, respectively)
plus SRL (target C0 8 ng/mL) [44]. In this study, in order to reach target
SRL C0 (8 ng/mL), signiﬁcantly higher doses of SRL were needed when
given with TAC than with CsA. The target C0 was not reached in the
TAC plus SRL group, even with the higher doses.5. Clinical outcomes with mTOR inhibitors and reduced
Tac exposure
The key randomized clinical studies that have assessed the use of
EVR or SRL in combination with TAC for immunosuppressive therapy
in the renal transplant setting are summarized in Table 1.
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The US09 trial (N = 92) was the ﬁrst prospective study to evalu-
ate concomitant use of EVR and TAC after renal transplantation. It
provided the ﬁrst evidence that EVR with low TAC doses is effective
and associated with good renal function [45]. Details on treatment
regimens for this and other studies in this section can be found in
Table 1. The primary efﬁcacy variable was the proportion of patients
with BPAR, and the primary safety variable was serum creatinine
level at 6 months. At 6 months, EVR/lower TAC exposure was not as-
sociated with worse renal function or reduced efﬁcacy, compared
with the EVR/standard TAC regimen, with similar improvement in
renal function (Table 1). The incidence of AEs was similar between
groups, although the incidence of anemia and arthralgia were more
frequent with standard-dose TAC and edema and peripheral edema
was higher with low-dose TAC. Although reduced-dose TAC with
EVR was not associated with any reduction in efﬁcacy, compared to
standard-dose TAC, the study was underpowered to detect a realistic
difference in renal function between the groups, and the results were
limited by the small difference in TAC exposure between the groups
(C0: 7.1 ± 5.3 ng/mL [reduced dose] vs 7.2 ± 2.5 ng/mL [standard
dose] at 6 months) [45].
A second study, ASSET (N= 224), investigated the potential of EVR
to allow minimization of TAC exposure to levels lower than previously
assessed (target C0 1.5–3 ng/mL) [46]. The primary objective was to
demonstrate superior estimated GFR at month 12 in the EVR/very-
low-dose TAC group versus the EVR/low-dose TAC group, and the sec-
ondary objective was the evaluation of the noninferiority of BPAR
(months 4–12) between groups. Safety endpoints included AEs and se-
rious AEs (SAEs). The GFR at month 12 was higher with very-low-dose
TAC than low-dose TAC (57.1 vs 51.7 mL/min/1.73 m2; p = 0.0299,
which was not signiﬁcant at the 0.025 level). The authors attributed
this to an overlapping of achieved TAC exposure in the 2 groups
(Fig. 4). The mean TAC C0 was above the target level in the tacrolimus
1.5–3 ng/mL group from month 4 onwards. Rates of BPAR (months
4–12) were very low and comparable between the groups (Table 1).
No relationshipwas evident between EVR and TAC levels and the occur-
rence of BPAR. In addition, rates of SAEs were also comparable between
the TAC groups. NODM was numerically less frequent in the very-low-
dose TAC group than in the low-dose TAC group (17.8% vs 20.5%, respec-
tively; p = 0.086). This study showed that EVR enabled TAC dose min-
imization (lower than studied previously) while achieving good renal
function, low BPAR and graft-loss rates, and an acceptable safety proﬁle
over 12 months [46].
In the EVEROTAC study (N = 35), described earlier in this review,
rates of acute rejection were similar with both EVR 0.75-mg bid (20%)
and EVR 1.5-mg bid (15%) when used in combination with standard-
dose TAC [36]. Serum creatinine values declined progressively in both
groups over 6 months, with no signiﬁcant differences between groups,
indicating that this combination preserved graft function. Analysis of
the relationship of pharmacokinetic parameters with acute rejection
rates showed that, in the EVR 1.5-mg bid group, patients without
acute rejection had higher EVR day-14 C0 values (2.25 ± 1.18 ng/mL)
compared with patients who experienced acute rejection by day 14
(1.49 ± 0.63 ng/mL; p b 0.05). TAC exposure was not related to acute
rejection, regardless of EVR dosage.
These studies suggest that the use of concentration-controlled EVR
allows substantial minimization of TAC exposure to achieve good
renal function without compromising efﬁcacy or safety in de novo
renal transplant recipients. However, comparative data versus other
regimens are lacking at this time.
5.2. Sirolimus
Details on treatment regimens for the sirolimus studies discussed
in this section can be found in Table 1. The Australian ﬁndings (N =64) from a larger, global, randomized, open-label concentration-
controlled trial that examined the efﬁcacy and safety of SRL in com-
bination with reduced- or standard-dose TAC have been reported
[47]. The primary endpoint of the study was renal graft function.
Six-month patient survival, graft survival, BPAR incidence, GFR, and
mean serum creatinine levels were not signiﬁcantly different be-
tween the groups. The study showed that reduction in TAC exposure
by 50% in combination with concentration-controlled dosing of SRL
with steroids produced a trend toward better renal function and
led to similar efﬁcacy as with standard-dose TAC [47].
Another study examined the efﬁcacy of SRL-based TAC-sparing and
TAC-free regimens in 70 high-risk patients undergoing renal transplan-
tation from a deceased donor [48]. The study outcomes were patient
survival and graft survival, BPAR, and creatinine clearance. The only sig-
niﬁcant (p b 0.05) difference was observed for creatinine clearance,
which was signiﬁcantly higher (by 21.9 mL/min) in the TAC-free
group (SRL/MMF) than the SRL/TAC-sparing group (Table 1). Similar
toxicity proﬁles (hospital readmission, infection, wound complications,
and metabolic complications) were seen with both regimens. Both reg-
imens were safe and effective in patients with a high immunologic risk,
but the TAC-free regimen was associated with better renal function
at 1-year posttransplant [48]. A smaller study (N = 39) by the same
group reported no differences in patient survival, graft survival, or
BPAR incidence between patients receiving SRL/standard TAC and
those receiving SRL/reduced TAC (Table 1) [49]. However, 38% and 6%
of patients on standard TAC were discontinued due to TAC nephrotoxi-
city and thrombotic microangiopathy, respectively. Several factors may
have contributed to the apparent increased nephrotoxicity, including
the study population (79% black), use of kidneys from deceased donors,
and high incidence of delayed graft function (59%).
Two-year data compared similar regimens in 132 live donor renal
allotransplant patients [50]. The efﬁcacy outcomes were patient
survival and graft survival, BPAR incidence, and graft function. At
2 years, renal function was signiﬁcantly improved with the TAC-
free regimen (SRL/MMF), compared with the SRL/TAC-sparing regi-
men, as measured by serum creatinine level and calculated GFR
(both p b 0.05; Table 1). In addition, the rate of acute rejection was
numerically lower in the TAC-free group (13.5% vs 18.5%; p = ns).
Three-year results from a long-term study (N = 150) comparing
SRL/TAC, MMF/TAC, and SRL/CsA are also available [51]. At 3 years, pa-
tient survival, graft survival, and BPAR incidence did not differ signiﬁ-
cantly among the 3 groups (Table 1), although the latter showed a
trend in favor of MMF/TAC (p = 0.07). Although renal function (as
measured by creatinine) was acceptable in each of the 3 groups, the
MMF/TAC group was statistically more favorable when compared with
SRL/CsA at 12, 24, and 36 months (p= 0.02, p= 0.05, andp= 0.04, re-
spectively) and SRL/TAC at 24 months (p = 0.05). Rates of NODM by
year 3 were lowest with MMF/TAC (11% vs 27–31% in other groups).
Longer-term follow-up of the same study (median of 8 years) showed
signiﬁcant differences or trends with respect to the above endpoints
that consistently favored MMF/TAC over the other regimens [52]. Viral
infections and need for antilipid therapy were signiﬁcantly lower with
MMF/TAC versus the other regimens combined (p b 0.05), and the inci-
dence of NODMwas numerically lower with MMF/TAC (Table 1). Simi-
lar long-term ﬁndings were reported by Chhabra and colleagues [53]. In
their study, 82 renal transplant recipients were followed for up to a
mean of 8.5 years. MMF/TAC provided better efﬁcacy and safety than
SRL/TAC, with signiﬁcant differences seen for graft survival and GFR
(Table 1).
In summary, results to date are derived mainly from single-center
studies, and thus more robust data are needed to conﬁrm the prelimi-
nary ﬁndings. Two small-scale studies compared reduced-dose TAC ver-
sus standard-dose TAC, when used in combination with SRL [47,49].
Efﬁcacy outcomes were similar between regimens in both studies [47,
49], but use of the lower dose of TAC was associated with less nephro-
toxicity in one study [49]. In comparative studies, the combination of
Table 1
Summary of randomized clinical trials ofmTOR inhibitors in combinationwith reduced-dose TAC in renal transplant recipients. Reprinted from Transplantation Proceedings, 38, Kovarik et al, Differential pharmacokinetic interaction of tacrolimus and
cyclosporine on everolimus, 3456-3458, (c) 2006, with permission from Elsevier. [33].
Trial Study design Interventions Efﬁcacy outcomes Safety outcomes
Everolimus
US09 [45] 6-Month multicenter, prospective, ran-
domized, open-label study in de novo
renal transplant recipients
N = 92
Low TAC (C0, 4–7 ng/mL months 0–3 and
3–6 ng/mL months 4–6) vs standard TAC (C0,
8–11 ng/mL months 0–3 and 7–10 ng/mL months
4–6) with concentration-controlled EVR (adjusted
to maintain C0 N 3 ng/mL), basiliximab induction,
and steroids
• Renal function: similar improvement in serum
creatinine levels between low TAC and standard TAC
groups (112 ± 31 μmol/L and 127 ± 50 μmol/L)
• BPAR: similar rates at 6 months (14% in each group)
• No signiﬁcant differences between groups
• Similar incidence of SAEs or infections (22%
vs 33%)
• In low-TAC vs standard-TAC groups, inci-
dences of edema: 12.2% vs 9.3%; peripheral
edema: 47% vs 20.9%; anemia: 10.2% vs
23.3%; and NODM: 38% vs 24%
ASSET [46] 12-Month multicenter, open-label, ran-
domized study in de novo renal transplant
recipients
N = 224
Very low TAC (C0, 1.5–3 ng/mL) vs low TAC
(4–7 ng/mL) with concentration-controlled EVR
(adjusted to maintain C0 at 3–8 ng/mL),
basiliximab induction, and corticosteroids
Very low TAC vs low TAC:
• Renal function: similar GFR at 12 months (57.1 vs
51.7 mL/min/1.73 m2)
• BPAR: similar low rate in both groups (2.7% vs 1.1%)
Very low TAC vs low TAC:
• Comparable SAE rates in both groups
(58.7% vs 51.3%)
• Low incidence of NODM in both groups
(17.8% vs 20.5%)
EVEROTAC [36] 6-Month Spanish, multicenter, prospec-
tive, randomized, phase II, open-label
study in de novo renal transplant recipi-
ents
N = 35
EVR 0.75-mg bid vs 1.5-mg bid to day 42 (dose
adjustment thereafter to maintain level of
3–8 ng/mL) with standard TAC and steroids
• AE rate: similar for both groups (EVR 0.75-mg bid
group, 20%; EVR 1.5-mg bid group, 15%)
• Renal function: progressive improvement of SCr
values with no difference between groups
Infection was the most frequently reported
AE (22% EVR 0.75 mg bid group; 14% EVR
1.5 mg bid group)
Sirolimus
Russ et al., 2003 [47] 6-Month Australian, phase II, randomized,
multicenter, open-label study in de novo
renal transplant recipients
N = 64
• SRL (target 8–15 ng/mL) + reduced TAC
(target 3–7 ng/mL)
• SRL (target 5–10 ng/mL) + standard TAC
(8–12 ng/mL)
• Corticosteroids administered in both groups
Reduced TAC vs standard TAC:
• Patient survival: 94% vs 100%
• Graft survival: 91% vs 97%
• BPAR: 21% vs 19%
• GFR: 68 mL/min vs 62 mL/min
Similar rates of AEs, infections, and use of
antihyperlipidemic medications
Lo et al., 2004 [48] 12-Month randomized study in de novo
renal transplant recipients
N = 70
• TAC-sparing regimen: standard SRL (C0,
10–15 ng/mL) + reduced TAC (C0, 3–6 ng/mL)
• TAC-free regimen: full-dose SRL (C0,
12–15 ng/mL) + MMF (2-g daily)
• ATG and corticosteroids administered in both
groups
TAC sparing vs TAC free:
• Patient survival: 98% vs 100%
• Graft survival: 80% vs 89%
• BPAR: 10% vs 7%
• Estimated CrCl: 50.5 ± 20.8 mL/min vs
72.4 ± 20.0 mL/min (p b 0.05)
TAC sparing vs TAC free:
• Wound complications: 12% vs 7%
• Lymphocele: 12% vs 3.5%
• NODM: 27% vs 20%
• Polyoma virus infection: 0 vs 3 cases
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Lo et al., 2004 [49] 6-Month prospective, randomized study in
de novo renal transplant recipients
N = 39
• SRL (C0, 5–10 ng/mL) + standard TAC (C0,
10–15 ng/mL)
• SRL (C0, 10–15 ng/mL) + reduced TAC (C0,
5–10 ng/mL)
• ATG and corticosteroids administered in both
groups
Reduced TAC vs standard TAC:
• Patient survival: 100% vs 94%
• Graft survival: 83% vs 94%
• BPAR: 5% vs 6%
• Serum creatinine: 1.6 ± 0.9 mg/dL vs
1.9 ± 0.7 mg/dL
Standard TAC: 44% discontinued due to TAC
nephrotoxicity (38%) or thrombotic micro-
angiopathy (6%)
Hamdy et al., 2005 [50] 24-Month prospective, randomized study
in de novo renal transplant recipients
N = 132
• TAC-sparing regimen: standard SRL (C0,
6–12 ng/mL) +reduced TAC (C0, 3–7 ng/mL)
• TAC-free regimen: full-dose SRL (C0,
10–15 ng/mL) + MMF (2-g daily)
• Basiliximab and corticosteroids administered
in both groups
TAC sparing vs TAC free:
• Serum creatinine level at 24 months: 1.43 vs
1.25 mg/dL (p = 0.005)
• GFR at 24 months: 79.6 ± 25.5 vs 94.9 ± 28.9
(p = 0.005)
TAC sparing vs TAC free:
• Herpes zoster infections: 0 vs 7.4%
(p = 0.025)
• Proteinuria: 13.8% vs 29.8% (p = 0.026)
• Diarrhea: 18.4% vs 5.9% (p = 0.028)
Ciancio et al., 2006 [51] 36-Month prospective, randomized
study in de novo renal transplant recip-
ients
N = 150
• Group A (TACminimization): SRL (C0, 8 ng/mL) +
reduced TAC (C0, 10 ng/mL initially, reduced to
6–8 ng/mL frommonths 3–6, and to 6 ng/mL at
1 year)
• Group B: MMF (2-g daily) + standard TAC (C0,
10 ng/mL initially, decreased to 8 ng/mL by
1 year)
• Group C: SRL (C0, 8 ng/mL) + low-dose CsA
(C0 200–250 ng/mL initially, reduced to
150–200 ng/mL by 1 year)
Groups A, B, and C at year 3:
• Patient survival: 90%, 92%, 96%
• Graft survival: 82%, 88%, 88%
• BPAR: 26%, 10%, 20%
• Renal function: creatinine level (mg/dL): 1.39, 1.36,
1.60
• CrCl (mL/min): 72.8 ± 4.3, 72.1 ± 4.1, 61.8 ± 3.8
Groups A, B, and C at year 3:
Incidence of NODM: 27%, 11%, 31%,
respectively
Guerra et al., 2011 [52] Long-term (median of 8 years) follow-up
to Ciancio et al., 2006 [51]
• See Ciancio et al., 2006 [51] Groups A, B, and C:
• Any death: 34%, 15%, 6% (p = 0.002)
•Deathwith functioning graft: 30%, 14%, 5% (p = 0.01)
• Graft loss: 45%, 34%, 29%
• BPAR: 34%, 14%, 31%
• Creatinine level (mg/dL): 1.38, 1.15, 1.44
• GFR (mL/min/1.73 m2): 59.5 ± 4.2, 67.4 ± 6.2,
53.8 ± 4.2
Groups A, B, and C:
• Viral infections: 20%, 6%, 20% (p = 0.02 for
Group B vs Groups A + C combined)
• Need for antilipid therapy: 55%, 39%, 79%
(p = 0.007 for Group B vs Groups A + C
combined)
• NODM: 32%, 19%, 31%
Chhabra et al., 2012 [53] Long-term (mean of 8.5 years), prospec-
tive, randomized study in de novo renal
transplant recipients
N = 82
• SRL (C0, 7–10 ng/mL) + reduced TAC (C0,
6–8 ng/mL)
•MMF (2-g daily) + reduced TAC (C0, 6–8 ng/mL)
• Basiliximab and methylprednisolone adminis-
tered in both groups
SRL/TAC vs MMF/TAC:
• Patient survival: 91% vs 100% (p = 0.05)
• Graft survival: 70% vs 91% (p = 0.02)
• BPAR: 35% vs 18%
• GFR (mL/min/1.73 m2): 23.5 vs 54.1 (p b 0.001)
SRL/TAC vs MMF/TAC:
NODM: 24% vs 13%
Proteinuria (N1 g/day): 24% vs 11%
Infections: 24% vs 24%
P values are included in the table when differences were reported to be statistically signiﬁcant.
AE, adverse event; ATG, antithymocyte globulin; bid, twice daily; BPAR, biopsy-proven acute rejection; C0, trough concentration; CrCl, creatinine clearance; CsA, cyclosporine; EVR, everolimus; GFR, glomerular ﬁltration rate; MMF, mycophenolate
mofetil; NODM, new-onset diabetes mellitus; SAE, serious adverse event; SCr, serum creatinine; SRL, sirolimus; TAC, tacrolimus.
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in combination with TAC provided numerically or signiﬁcantly better
results in terms of patient/graft survival and BPAR [51–53], and both
MMF/TAC and SRL/MMF provided better renal function [48,50–53].6. Conclusion
CNIs remain the mainstay for maintenance immunosuppressive
therapy in renal transplantation, with TAC being the most widely
used. Although CNIs are associated with lower acute rejection rates,
improvements in long-term graft survival have been harder to achieve
[1] owing to nephrotoxicity that arises with long-term CNI use [3]. In
order to avoid nephrotoxicity, CNI-sparing/withdrawal strategies are
initiated early after transplantation, incorporating highly effective
nonnephrotoxic drugs. For example, the addition of mTOR inhibitors
(EVR or SLR)with their complementarymechanismof action and favor-
able nephrotoxicity proﬁle has enabled CNI reduction/withdrawal early
posttransplantation [1,4].
Consequently, the current management of immunosuppression in-
cludes the sequential use of different immunosuppressive drug combi-
nations over the lifetime of the graft. This increases the number and
complexity of potentially clinically relevant immunosuppressive drug
interactions, which require prompt identiﬁcation, concentration moni-
toring, and dose adjustments. TDM remains a major support in patient
management for assessing compliance, preventing AEs, and detecting
drug interactions. TDM can provide additional guidance to clinicians
on the risk of potential toxicity if blood drug levels are high or acute re-
jection if levels are subtherapeutic.
CNIs have a narrow therapeutic window and a high degree of inter-
and intra-individual pharmacokinetic variation, which present a
challenge when trying to achieve optimal dosing. Consequently,
TDM is required, usually by determining C0, in order to adjust treat-
ment in individual patients [15,16].
Pharmacokinetic studies have shown that mTOR inhibitors have
variable oral bioavailability and large intra- and inter-patient vari-
ability in drug exposure [18,26]. In addition, exposure–response
studies have determined that EVR and SRL have narrow therapeutic
windows (3–8 ng/mL and 5–15 ng/mL, respectively). Because of
these factors and the limited and inconsistent information on phar-
macokinetic interactions between CNIs and mTOR inhibitors, it ap-
pears prudent to monitor drug levels when the dose of either agent
is adjusted. For both EVR and SRL, there is a good correlation be-
tween C0 and AUC, which allows C0 to be used as a convenient andFig. 4.Mean tacrolimus C0 levels [46]. D, day; C0, trough concentration; EVR, e
Figure taken from Langer et al. 2012 (c) 2012. The Authors. Transplant Internareliable measure of drug exposure, and is also a good indicator of
clinical outcomes (improved efﬁcacy and reduced toxicity) [54,55].
Routine TDM of EVR and SRL blood concentrations are recom-
mended to maintain whole blood C0 concentrations of 3–8 ng/mL
and 5–15 ng/mL, respectively. As SRL has a long-half-life, C0 obtained
5–7 days after the start of treatment or dosage change should be used
to determine dose adjustments while 4 days at the most is needed for
EVR owing to its shorter half-life. After the initial dose titration, weekly
SRL C0measurements during the ﬁrst month, then every 2 weeks, have
been recommended [55]. There are several assays available to measure
blood mTOR inhibitor levels, with High-Pressure Liquid Chromatogra-
phy coupled with Mass Spectrometry (HPLC/MS) being the most accu-
rate and speciﬁc method. Immunoassay is also a reliable and more
convenient alternative. It is important to know which assay is being
used, as immunoassaysmay lead to overestimation of EVR and SRL con-
centrations as a result of cross-reactivity with metabolites [56].
Differences in immunosuppressive dosages and regimens among
the studies make it difﬁcult to determine the optimum dosing strategy
for TAC with mTOR inhibitors. Therapeutic target ranges for TAC when
used in combinationwith EVR or SRL are not as yet established. It should
be remembered, however, that higher doses of mTOR inhibitors are re-
quired when administered with TAC than with CsA [44]. In general,
there is little interaction between TAC andmTOR inhibitors, whereas
interactions between CsA and mTOR inhibitors are more pronounced
and result in higher blood levels of mTOR inhibitors [40,44]. Conse-
quently, higher starting doses of EVR are needed when combined with
low-dose TAC than with CsA to prevent increased risk of rejection. In
addition, careful concentrationmonitoring of both EVR and SRL is advis-
able when patients are switched between CNIs [34]. The EVR/CsA inter-
action is one of the reasons twice-daily dosing is recommended for EVR.
Clinical data on the use of EVR or SRL in TACminimization strategies
in renal transplantation are limited. Available evidence suggests that
treatment with EVR allows early and substantial TAC minimization
when used with basiliximab induction and corticosteroids. The lack of
clear differentiation in TAC exposure between standard- and reduced-
dose TAC groups in the US09 and ASSET studies highlights ongoing reluc-
tance to reduce CNI exposure even in the presence of EVR. SRL has also
been used successfully as part of a TAC-minimization strategy, resulting
in similar efﬁcacy and less nephrotoxicity when compared with SRL/
standard TAC. However, comparative studies support the use of
other regimens (e.g., SRL/MMF,MMF/TAC) over SRL/TAC in this popula-
tion. The ﬁndings with SRL, however, reﬂect single-center experiences.
AEs are common in all transplant patients receiving immunosup-
pressive therapy. Several safety concerns may arise from using anverolimus; M, month; SD, standard deviation; TAC, tacrolimus; W, week.
tional. (c) 2012 European Society for Organ Transplantation.
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lished literature by Peddi and colleagues found low rates of infection
(BK, cytomegalovirus, and Epstein–Barr virus) and malignancy
(0–7%), regardless of the transplant population (kidney, liver,
heart, or lung) [57]. Proteinuria, which is known to be associated
with mTOR inhibitors whereas a protective effect has been demon-
strated with CNIs, also occurred at a low incidence. No meaningful
differences were observed in rates of proteinuria, regardless of
whether the mTOR inhibitor was combined with reduced TAC or
with standard TAC. Other AEs were more commonly identiﬁed, in-
cluding dyslipidemia in up to two thirds of patients, NODM in up to
38%, wound complications in up to 22%, and hypertension in up to
17% [57]. Evidence also suggests that mTOR inhibitors may prolong
the duration of delayed graft function, deﬁned as the need for dialy-
sis within the ﬁrst 7 days posttransplant [58]. Consequently, many of
the studies we evaluated had exclusions for expected delayed graft
function.
Several stepsmay be taken to help reduce the incidence of someAEs,
such as maintaining mTOR inhibitor or TAC values within target ranges.
Among kidney transplant recipients, proteinuria was more common
when C0 levels of EVRwere N8 ng/mL comparedwith 3–8 ng/mL (haz-
ard ratio 1.84; p b 0.001) [59]. A progressive reduction in TAC target
levels has been proposed to help lower the incidence of NODM [60]. Be-
yond the use of immunosuppressive drugs, patients may have addition-
al risk factors that increase susceptibility to certain events. The risk for
NODM, for example, may be increased in black or Hispanic patients as
well as those who are older, obese, hepatitis C positive, have a family
history of diabetes, or received a transplant from a deceased donor
[60]. Risk factors for delayed graft function include donor age
N55 years, recipient age N60 years, cold ischemia time ≥24 h, and
retransplantation [61]. It is important to monitor patients for the
above AEs and to be aware of associated risk factors. Prompt implemen-
tation of lifestyle changes and/or pharmacologic therapy may be
necessary.
Several areas need to be addressed to optimize the use of a TAC-
minimization strategy with mTOR inhibitors. It is important to deter-
mine the therapeutic window for TACwhen usedwithmTOR inhibitors.
In addition, there is a need to further assess how this strategy compares
with other regimens (particularly for EVR/TAC), long-term outcomes
with mTOR inhibitor/TAC combination therapy, and efﬁcacy and safety
of this combination in renal transplant patients at high immunologic
risk.
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